Arcturus Therapeutics

Arcturus Therapeutics Holdings, Inc. develops pharmaceuticals. It is a clinical-stage mRNA medicines and vaccines company, which focuses on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. The firm's products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Arcturus Therapeutics reports robust earnings and advances in mRNA pipeline

Arcturus Therapeutics delivered strong financial results and showcased progress across key strategic areas
The company's collaborations, advancements in RNA technology, and clinical trial milestones position it for future success
While facing competition and challenges, Arcturus has opportunities to leverage its strengths and drive growth in the mRNA space

Arcturus reports strong Q1 earnings, advances COVID vaccine development

Arcturus Therapeutics demonstrated robust financial performance, progress in COVID-19 vaccine development, and advancements in mRNA therapeutics.
While facing challenges in drug safety and regulatory approvals, the company is well-positioned to capitalize on opportunities for expansion and innovation.
Strategic collaborations and a strong cash position enhance Arcturus' competitive edge and potential for sustained growth in the biopharmaceutical sector.

Arcturus Therapeutics reports Q2 results, advances key programs with CSL

Arcturus Therapeutics showcased financial resilience with a strong cash position and promising program advancements in Q2 2023.
While facing challenges such as high operating expenses and uncertainties in clinical trials, the company is leveraging opportunities for market expansion and program advancement.
Collaboration with CSL and progress on key programs like ARCT-154 and ARCT-810 position Arcturus for continued growth and innovation in the biopharmaceutical space.
Investors can look forward to data releases, program updates, and potential market expansions as Arcturus navigates financial challenges and capitalizes on growth opportunities.

Arcturus Therapeutics excels in Q3 with promising pipeline advancements

Arcturus Therapeutics demonstrated strong financial performance, operational efficiency, and clinical progress in key pipeline candidates, positioning the company for future growth and success.
The company's technological strengths, diverse pipeline, and strategic partnerships underscore its innovation and commitment to addressing unmet medical needs, enhancing market competitiveness.
While facing challenges in regulatory approvals and study outcomes, Arcturus has opportunities to expand its product portfolio, leverage mRNA technology advantages, and drive market growth through strategic planning.
Overall, Arcturus' Q3 earnings call highlights a balanced outlook of financial stability, clinical advancements, and strategic opportunities, signaling a positive trajectory for the company's future.

Arcturus Therapeutics reports mixed financials but strong vaccine pipeline

Arcturus Therapeutics faces financial challenges with expenses exceeding revenues, but maintains a stable cash runway and strong pipeline of vaccine programs
The company's focus on vaccine development for various diseases and mRNA therapeutics showcases promising strengths and diversification in its product offerings
Opportunities in the Japanese market, upcoming Phase II study results, and operational advancements present avenues for growth and value creation for Arcturus

Arcturus reports Q1 results, eyes growth through clinical progress

Arcturus Therapeutics reported mixed financial results in Q1 2024 but remains well-positioned with strong cash reserves and ongoing clinical advancements.
Challenges include managing expenses, revenue variability, and timing uncertainties in future guidance tied to Kostaive revenues.
However, opportunities lie in positive trial outcomes, potential milestone payments, and strategic alignment with global health initiatives.
Overall, Arcturus shows promise in its financial stability, clinical progress, and strategic positioning for future growth and innovation.

Arcturus Therapeutics excels in Q2 2024, poised for mRNA innovation

Arcturus Therapeutics demonstrated strong financial performance and progress in key programs, supported by a solid cash position and strategic collaborations.
While facing challenges such as cost management and regulatory complexities, the company is well-positioned to leverage opportunities in mRNA therapeutics and vaccine development.
Overall, Arcturus shows promise in advancing its pipeline and capturing growth opportunities in the evolving biopharmaceutical landscape.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Potential for highly differentiated COVID-19 vaccine profile  with a single administration, at a low dose

Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study

Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q2 2020 Results - Earnings Call Transcript

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -3.77% and -54.31%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Misses Revenue Estimates

COVID-19 STARR™ mRNA vaccine candidate, ARCT-021 (LUNAR-COV19) has initiated Phase 1/2 clinical study with Duke-NUS Medical School; Dosing anticipated imminently, initial data expected Q4

Arcturus Therapeutics Announces Second Quarter 2020 Financial Results and  Provides a Corporate Update

Arcturus Therapeutics (ARCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Arcturus Therapeutics (ARCT)?

AvroBio Inc

89bio Inc

Fulcrum Therapeutics Inc

Intercept Pharma

Let us take a look at some biotech stocks that are poised to beat on second-quarter earnings.

5 Biotech Stocks Set to Outpace Q2 Earnings Estimates

Nationally recognized leader in corporate life sciences transactions Nationally recognized leader in corporate life sciences transactions

Arcturus Therapeutics Appoints Lance Kurata as Chief Legal Officer

iBio

Vaxart

The potential rewards are high. But so are the risks.

3 Small-Cap Coronavirus Stocks That Could Skyrocket

SAN DIEGO, July  31, 2020  (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, announced the closing on July 31, 2020 of its previously announced underwritten public offering of 3,753,773 shares of its common stock at a public offering price of $53.00 per share, which included the exercise in full by the underwriters of their option to purchase up to an additional 489,622 shares of common stock at the public offering price, less underwriting discounts and commissions. Arcturus received total gross proceeds from the offering (before deducting the underwriting discounts and offering expenses) of approximately $200 million. The Company intends to use the net proceeds of the offering to develop, test and manufacture the Company’s LUNAR-COV19 vaccine candidate and to continue clinical development of LUNAR-OTC; to advance the Company’s LUNAR-CF, LUNAR-CV and LUNAR-FLU preclinical programs into clinical development; to fund early research and development of novel and proprietary RNA medicines; and for general corporate and working capital purposes.

Arcturus Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

BioNTech SE

Moderna

Telesis Bio Inc

If coronavirus vaccine development efforts are a race, then pharmaceutical companies will need to hurdle more than clinical trials to be successful.

Coronavirus Vaccine Stocks: Investors Cannot Overlook These Risks

SAN DIEGO, July  29, 2020  (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced the pricing of an underwritten public offering of 3,264,151 shares of its common stock at a public offering price of $53.00 per share. The gross proceeds of the offering to the Company are expected to be approximately $173.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses. In addition, the Company granted the underwriters a thirty-day option to purchase up to an additional 489,622 shares of common stock at the public offering price, less underwriting discounts and commissions.

Arcturus Therapeutics Announces Pricing of $173.0 Million Public Offering of Common Stock

Israel secures rights to stockpile and reserve doses of LUNAR-COV19 for its citizens

Arcturus Therapeutics Announces Agreement with Israeli Ministry of Health to Supply COVID-19 Vaccine Candidate, LUNAR-COV19

Human dosing of LUNAR-COV19 expected soon

Arcturus Therapeutics & Duke-NUS Received Approval to Proceed with Phase 1/2 Clinical Trial for COVID-19 Vaccine Candidate, LUNAR-COV19

Arcturus Therapeutics (ARCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Arcturus Therapeutics (ARCT) Rating Upgrade to Buy

Renowned experts in virology, infectious disease, vaccine development and public health to support Arcturus’ COVID-19 vaccine program, LUNAR-COV19

Arcturus Therapeutics Announces the Formation of its Vaccine Platform Scientific Advisory Board

SAN DIEGO, June  29, 2020  (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced that it will be added to the Russell 2000® Index, as part of the 2020 Russell indexes reconstitution. The addition will be effective after the U.S. market opens on June 29, 2020 as part of the 2020 Russell U.S. Indexes annual reconstitution.

Arcturus Therapeutics to be Added to Russell 2000® Index

SAN DIEGO, June  11, 2020  (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced that Joseph Payne, President and Chief Executive Officer of Arcturus, will present at the Raymond James Human Health Innovation Conference, being held virtually during June 15-18, 2020.

Arcturus Therapeutics to Present at the Raymond James Human Health Innovation Virtual Conference

SAN DIEGO, June  05, 2020  (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced that it has dosed the first healthy volunteer in a Phase 1 study with ARCT-810, the Company’s messenger RNA (mRNA)-based therapeutic candidate for Ornithine Transcarbamylase (OTC) deficiency.

Arcturus Therapeutics Announces First Healthy Volunteer Dosed in Phase 1 Study of ARCT-810 for Ornithine Transcarbamylase (OTC) Deficiency

After Plummeting Over 30%, Are Arcturus Therapeutics Shares Still a Good Buy?

Dynavax Technologies

Inovio Pharmaceuticals

Novavax

Sorrento Therapeutics Inc

A race to develop a coronavirus vaccine is on, and these red-hot Covid-19 vaccine stocks are leading the way.

7 Red-Hot Biotech Stocks Racing to Develop a Coronavirus Vaccine

Ultragenyx Pharmaceutical

NOVATO, Calif. and SAN DIEGO, May  21, 2020  (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical, Inc. (Nasdaq: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases and Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT), a leading messenger RNA medicines company, today announced that Ultragenyx has exercised its option to purchase 600,000 shares of Arcturus common stock at $16.00 per share.

Ultragenyx Announces Exercise of Option to Purchase Additional Stock of Arcturus Therapeutics

Arcturus Therapeutics (ARCT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Is Arcturus Therapeutics (ARCT) Stock a Solid Choice Right Now?

Arcturus Therapeutics' (ARCT) CEO Joseph Payne on Q1 2020 Results - Earnings Call Transcript

New data provides evidence of adaptive cellular (CD8+ cells) and balanced (Th1/Th2) immune responses

Arcturus Reports Additional Supportive Preclinical Data for its COVID-19 Vaccine Candidate (LUNAR-COV19)

Catalent

SAN DIEGO and SOMERSET, N.J., May  04, 2020  (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (“Arcturus”, “the Company”, Nasdaq: ARCT), a leading clinical-stage messenger RNA (mRNA) medicines and vaccines company, and Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced a partnership to support the expected manufacture of Arcturus’ COVID-19 mRNA vaccine candidate (LUNAR-COV19), intended to protect against the SARS-CoV-2 coronavirus.

News for Arcturus Therapeutics Stock (ARCT)